SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC

QIDP provides five additional years of market exclusivity, and Fast Track expedites the regulatory path

Enrollment completed in Phase 2b DOVE study in VVC; on-track for top-line data by July 2018

Initiation of Phase 3 registration program in VVC plan... Biopharmaceuticals, FDA SCYNEXIS, SCY-078, antifungal, candidiasis

Source: HSMN NewsFeed - May 1, 2018 Category: Pharmaceuticals Source Type: news